转录因子E2F1在乳腺浸润性导管癌组织中的表达及其临床意义

Expression and Clinical Significances of Transcription Factor E2F1 in Breast Invasive Ductal Carcinoma

目的检测转录因子E2F1在乳腺浸润性导管癌(IDC)组织中的表达及其在IDC发生、发展中的作用。方法采用免疫组化S-P法检测91例乳腺IDC组织、18例不典型增生组织、30例正常乳腺组织中E2F1蛋白表达情况。结果 91例乳腺IDC组织、18例不典型增生组织及30例正常乳腺组织中E2F1蛋白阳性表达率分别为47.3%(43/91)、11.1%(2/18)和0.0%(0/30),差异有统计学意义(P<0.05)。IDC组织中E2F1蛋白表达与腋窝淋巴结转移、肿瘤大小、组织学分级、TNM分期及ER、PR状态有关(P<0.05)。结论 E2F1在IDC组织中高表达,可能是参与乳腺IDC病程进展的重要因子,可作为预测乳腺IDC淋巴结转移及预后评估的指标。

Objective To evaluate the expression of E2F1 protein and the correlations with carcinogenesis and progression in breast invasive dutcal carcinoma （IDC）. Methods The immunohistochemical S-P method was used to detect the expression of E2F1 in the 91 cases of breast IDC, 18 cases of atypical hyperplasia and 30 cases of nor- mal breast tissues. Results There were statistical differences in the positive rate of E2F1 among the breast IDC [47.3% （43/91） ] ,the atypical hyperplasia[ 11.1% （2/18） ] and the normal breast tissues[0.0% （0/30） ] （P 〈 0.05 ）. The expression of E2F1 was correlated with lymph node metastasis, tumor size, histological grading, TNM tumor stage, ER and PR status （ P 〈 0.05 ）. Conclusion E2F1 is up-regulated in the breast IDC, and is associated with the progression of breast IDC, E2F1 might be a novel molecular marker to predict lymph node metastasis and prognosis of breast IDC.